399 related articles for article (PubMed ID: 26409607)
21. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
Vanagas G; Padaiga Z; Mickevičienė A
Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
[TBL] [Abstract][Full Text] [Related]
22. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
[TBL] [Abstract][Full Text] [Related]
23. Telbivudine for the treatment of chronic hepatitis B infection.
Hartwell D; Jones J; Harris P; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
Wu B; Shen J; Cheng H
BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.
Goyal A; Murray JM
Clin Drug Investig; 2016 Aug; 36(8):637-48. PubMed ID: 27166628
[TBL] [Abstract][Full Text] [Related]
28. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
Veenstra DL; Spackman DE; Di Bisceglie A; Kowdley KV; Gish RG
Aliment Pharmacol Ther; 2008 Jun; 27(12):1240-52. PubMed ID: 18373637
[TBL] [Abstract][Full Text] [Related]
29. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis.
Govan L; Wu O; Xin Y; Hutchinson SJ; Hawkins N
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):882-94. PubMed ID: 25919772
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
Toy M; Hutton DW; So SK
PLoS One; 2015; 10(11):e0139876. PubMed ID: 26536626
[TBL] [Abstract][Full Text] [Related]
32. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
33. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Viganò M; Invernizzi F; Lampertico P
Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
[TBL] [Abstract][Full Text] [Related]
34. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B.
Lo AO; Wong VW; Wong GL; Chan HL; Dan YY
Clin Gastroenterol Hepatol; 2015 Feb; 13(2):377-385.e5. PubMed ID: 24993366
[TBL] [Abstract][Full Text] [Related]
36. First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China.
Yin XR; Liu ZH; Liu J; Liu YY; Xie L; Tao LB; Jia JD; Cui FQ; Zhuang GH; Hou JL
Chin Med J (Engl); 2019 Oct; 132(19):2315-2324. PubMed ID: 31567376
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China.
Dai Z; Wong IOL; Xie C; Xu W; Xiang Y; Peng L; Lau EHY
Clin Microbiol Infect; 2022 Feb; 28(2):300.e1-300.e8. PubMed ID: 34197929
[TBL] [Abstract][Full Text] [Related]
38. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]